Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Trial ID or NCT#
NCT00490776
Status
NOT RECRUITING
Purpose
This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.
Official Title
A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Sunil Arani Reddy
Medical oncologist,
Cutaneous oncology specialist
Clinical Associate Professor, Medicine - Oncology
Contact us to find out if this trial is right for you.
Contact
Natalie Viakhireva
6507238949
View on ClinicalTrials.gov
